Evidence map›Paper›PMID 40591028›Full record

ArticleNeurosurgical review2025

Magnesium sulfate in combination with nimodipine in non-traumatic subarachnoid hemorrhage: a retrospective analysis of short- and long-term mortality.

Hui Shen, Yibo Yang, Qing Mei, Zhenkun Xiao, Bing Wang, Aihua Liu

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Hui Shen *Cerebrovascular Disease Department, Neurological Disease Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yibo Yang *The Second Affiliated Hospital, Department of Neurosurgery, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Qing Mei *Department of Neurology, Beijing Pinggu Hospital, Beijing, China.
Zhenkun XiaoThe Second Affiliated Hospital, Department of Neurosurgery, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
Bing WangCerebrovascular Disease Department, Neurological Disease Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. wangbing@usc.edu.cn.
Aihua LiuCerebrovascular Disease Department, Neurological Disease Center, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. liuaihuadoctor@163.com.

Funding

Natural Science Foundation of China 81771233Ningxia Key Scientific and Technological Achievement Transformation Project 2024CJE09005Ningxia Natural Science Foundation Key Project 2024AAC02066
6 · The paper itself

Abstract

backgroundSubarachnoid hemorrhage (SAH) is a severe neurological condition with high rates of disability and mortality. Although nimodipine is widely used in the treatment of SAH, the potential benefits of magnesium as an adjunct therapy remain unclear. The aim of this study was to explore the impact of magnesium sulfate combined with nimodipine on mortality in patients with non-traumatic SAH (NSAH).

methodsThis retrospective cohort study was based on the Medical Information Mart for Intensive Care IV (MIMIC-IV) database, including critically ill patients with NSAH. Patients were categorized into a combined group (N + M) and a nimodipine-only group (N) based on their use of magnesium sulfate and nimodipine during their ICU stay. The primary outcome was one-month all-cause mortality, while the secondary outcome was one-year all-cause mortality. Multivariable analysis was used to adjust for confounding factors. Landmark analysis was performed to assess both short-term and long-term effects.

resultsA total of 587 patients were included in the study, with 280 in the N + M group. The one-month and one-year all-cause mortality rate were 15% and 20%, respectively, for the N + M group, compared to 7.2% and 9.1% for the N group. The use of magnesium sulfate was associated with higher one-month (HR 1.89 [95% CI 1.09-3.27]) and one-year (HR 2.08 [95% CI 1.29-3.36]) mortality. Landmark analysis showed that the mortality risk between the two groups remained consistent from two months to one year.

conclusionIn critically ill NSAH patients, the combination of magnesium sulfate and nimodipine was associated with increased all-cause mortality compared to nimodipine alone. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Magnesium SulfateNimodipineSubarachnoid HemorrhageVasodilator AgentsAdultAgedCohort StudiesDrug Therapy, CombinationFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeMagnesium SulfateNimodipineVasodilator AgentsDelayed cerebral ischemiaMagnesium sulfateMedical information mart for intensive care IV databaseMortalityNimodipineNon-traumatic subarachnoid hemorrhage

Identifiers

PMID40591028

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.